Announcement • Jun 30
BGI Genomics Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026 BGI Genomics Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026 Announcement • Jun 17
BGI Genomics Co., Ltd. (SZSE:300676) announces an Equity Buyback for CNY 500 million worth of its shares. BGI Genomics Co., Ltd. (SZSE:300676) announces a share repurchase program. Under the program, the company will repurchase up to CNY 500 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 50 per share. The shares purchased will be used for the company's equity incentive plan or employee stock ownership plans. The program will be funded out of the own funds and self-raised funds (including special loans for stock repurchase from financial institutions. The program will be valid till 12 months from board approval date. Reported Earnings • Apr 25
First quarter 2026 earnings released: CN¥0.023 loss per share (vs CN¥0.13 loss in 1Q 2025) First quarter 2026 results: CN¥0.023 loss per share (improved from CN¥0.13 loss in 1Q 2025). Revenue: CN¥808.7m (up 20% from 1Q 2025). Net loss: CN¥9.52m (loss narrowed 82% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Announcement • Apr 25
BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2026 BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2026, at 14:30 China Standard Time. Location: Zone C, No. 9, Yunhua Road, Meisha Subdistrict, Yantian District, Shenzhen, Guangdong China New Risk • Apr 07
New major risk - Revenue and earnings growth Earnings have declined by 71% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Mar 31
BGI Genomics Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 BGI Genomics Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Announcement • Dec 31
BGI Genomics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 BGI Genomics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 24
Third quarter 2025 earnings released: CN¥0.065 loss per share (vs CN¥0.36 loss in 3Q 2024) Third quarter 2025 results: CN¥0.065 loss per share (improved from CN¥0.36 loss in 3Q 2024). Revenue: CN¥1.04b (up 9.2% from 3Q 2024). Net loss: CN¥27.2m (loss narrowed 81% from 3Q 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 121 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
BGI Genomics Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025 BGI Genomics Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025 Announcement • Sep 23
An undisclosed buyer acquired 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. for Approximately CNY 740 million. An undisclosed buyer acquired 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. for Approximately CNY 740 million on September 22, 2025.
An undisclosed buyer completed the acquisition of 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. on September 22, 2025. Reported Earnings • Aug 23
Second quarter 2025 earnings released: EPS: CN¥0.14 (vs CN¥0.013 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.14 (up from CN¥0.013 in 2Q 2024). Revenue: CN¥959.6m (down 8.6% from 2Q 2024). Net income: CN¥58.5m (up CN¥52.7m from 2Q 2024). Profit margin: 6.1% (up from 0.6% in 2Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 123 percentage points per year, which is a significant difference in performance. Announcement • Jul 02
BGI Genomics Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025 BGI Genomics Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Reported Earnings • Apr 26
First quarter 2025 earnings released: CN¥0.13 loss per share (vs CN¥0.03 profit in 1Q 2024) First quarter 2025 results: CN¥0.13 loss per share (down from CN¥0.03 profit in 1Q 2024). Revenue: CN¥671.9m (down 18% from 1Q 2024). Net loss: CN¥52.7m (down CN¥65.1m from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance. Announcement • Apr 26
BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2025 BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: Area C, No. 9, Yunhua Road, Meisha Subdistrict, Yantian District, Shenzhen, Guangdong China New Risk • Apr 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 32% per year over the past 5 years. Announcement • Mar 31
BGI Genomics Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 BGI Genomics Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 New Risk • Feb 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 32% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Announcement • Dec 31
BGI Genomics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 BGI Genomics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.045 profit in 3Q 2023) Third quarter 2024 results: CN¥0.36 loss per share (down from CN¥0.045 profit in 3Q 2023). Revenue: CN¥954.5m (down 11% from 3Q 2023). Net loss: CN¥142.4m (down CN¥161.0m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
BGI Genomics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 BGI Genomics Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.027 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.013 (down from CN¥0.027 in 2Q 2023). Revenue: CN¥1.05b (down 6.0% from 2Q 2023). Net income: CN¥5.80m (down 44% from 2Q 2023). Profit margin: 0.6% (down from 0.9% in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance. Board Change • Jul 18
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non Independent Director Yujue Wang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 29
BGI Genomics Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024 BGI Genomics Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 Announcement • Jun 28
BGI Genomics Co., Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 4 July 2024 BGI Genomics Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): cash dividend of CNY 1.0000000 per ten shares (tax included) for the year 2023. Record date is 3 July 2024. Ex-date is 4 July 2024. Payment date is 4 July 2024. Announcement • Jun 20
BGI Genomics Co., Ltd. Announces Board Appointments BGI Genomics Co., Ltd. announced at the EGM held on June 18, 2024, approved election of Zhu Shida, Zhang Guocheng and Wang Yujue as non-independent director and Hou Zhibo, independent director. Announcement • May 11
Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023 BGI Genomics Co., Ltd. announced at the AGM held on May 9, 2024, approved Cash dividend/10 shares (tax included): CNY 1.00000000 for 2023. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.091 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.03 (down from CN¥0.091 in 1Q 2023). Revenue: CN¥821.3m (down 14% from 1Q 2023). Net income: CN¥12.4m (down 70% from 1Q 2023). Profit margin: 1.5% (down from 4.3% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 15
Full year 2023 earnings released: EPS: CN¥0.23 (vs CN¥1.96 in FY 2022) Full year 2023 results: EPS: CN¥0.23 (down from CN¥1.96 in FY 2022). Revenue: CN¥4.35b (down 38% from FY 2022). Net income: CN¥92.9m (down 88% from FY 2022). Profit margin: 2.1% (down from 11% in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance. Announcement • Apr 13
BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024 BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024, at 14:00 China Standard Time. Announcement • Mar 30
BGI Genomics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 BGI Genomics Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Reported Earnings • Mar 01
Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥1.96 in FY 2022) Full year 2023 results: EPS: CN¥0.22 (down from CN¥1.96 in FY 2022). Revenue: CN¥4.35b (down 38% from FY 2022). Net income: CN¥91.2m (down 89% from FY 2022). Profit margin: 2.1% (down from 11% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance. Announcement • Dec 29
BGI Genomics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024 BGI Genomics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 13, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.35 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.045 (down from CN¥0.35 in 3Q 2022). Revenue: CN¥1.07b (down 21% from 3Q 2022). Net income: CN¥18.6m (down 87% from 3Q 2022). Profit margin: 1.7% (down from 11% in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance. New Risk • Aug 13
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 167% The company is paying a dividend despite having no free cash flows. Dividend yield: 1.7% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 167% Paying a dividend despite having no free cash flows. High level of non-cash earnings (36% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (4.2% net profit margin). Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.68 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.027 (down from CN¥0.68 in 2Q 2022). Revenue: CN¥1.12b (down 36% from 2Q 2022). Net income: CN¥10.4m (down 96% from 2Q 2022). Profit margin: 0.9% (down from 16% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Announcement • Jul 01
BGI Genomics Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023 BGI Genomics Co., Ltd. announced that they will report first half, 2023 results on Aug 12, 2023 Announcement • Jun 01
Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023 BGI Genomics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): cash dividend of CNY 10.0000000 per ten shares (tax included) for the year 2022. Record date is 06 June 2023. Ex-date is 07 June 2023. Payment date is 07 June 2023. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.81 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.091 (down from CN¥0.81 in 1Q 2022). Revenue: CN¥953.8m (down 33% from 1Q 2022). Net income: CN¥41.3m (down 88% from 1Q 2022). Profit margin: 4.3% (down from 23% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to CN¥75.83, the stock trades at a trailing P/E ratio of 39.2x. Average trailing P/E is 41x in the Biotechs industry in China. Total loss to shareholders of 6.9% over the past three years. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ya Cao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.80 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.35 (down from CN¥0.80 in 3Q 2021). Revenue: CN¥1.35b (down 10% from 3Q 2021). Net income: CN¥141.4m (down 57% from 3Q 2021). Profit margin: 11% (down from 22% in 3Q 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥20.98 (vs CN¥1.37 in 2Q 2021) Second quarter 2022 results: EPS: CN¥20.98 (up from CN¥1.37 in 2Q 2021). Revenue: CN¥25.7b (up CN¥23.6b from 2Q 2021). Net income: CN¥1.47b (up 162% from 2Q 2021). Profit margin: 5.7% (down from 27% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 63% compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Jun 29
BGI Genomics Announces Final Profit Distribution for 2021 payable on 06 July 2022 BGI Genomics Co., Ltd. announced 2021 final profit distribution plan to be implemented (A shares). Cash dividend/10 shares (tax included) of CNY 3.50000000. Record date: 05 July 2022; Ex-date: 06 July 2022; Payment date: 06 July 2022. Announcement • May 20
BGI Genomics Co., Ltd. Approves Cash Dividend for the Year 2021 BGI Genomics Co., Ltd. announced that at its Annual General Meeting held on 18 May 2022, approved cash dividend/10 shares (tax included) of CNY 3.50000000 for the year 2021. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: EPS: CN¥0.81 (down from CN¥1.29 in 1Q 2021). Revenue: CN¥1.43b (down 8.5% from 1Q 2021). Net income: CN¥330.4m (down 37% from 1Q 2021). Profit margin: 23% (down from 34% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) exceeded analyst estimates by 15%. Over the next year, revenue is expected to shrink by 18% compared to a 44% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ya Cao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Apr 26
BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2021 BGI Genomics Co., Ltd. announced on April 25, 2022 the profit distribution proposal for 2021 as cash dividend/10 shares (tax included) of CNY 3.50000000. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥98.32, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 35x in the Biotechs industry in China. Total returns to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.53 per share. Reported Earnings • Feb 28
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: EPS: CN¥3.48 (down from CN¥5.25 in FY 2020). Revenue: CN¥6.70b (down 20% from FY 2020). Net income: CN¥1.43b (down 32% from FY 2020). Profit margin: 21% (down from 25% in FY 2020). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 17%, compared to a 37% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥1.37 (vs CN¥3.79 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥2.08b (down 37% from 2Q 2020). Net income: CN¥561.0m (down 63% from 2Q 2020). Profit margin: 27% (down from 46% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Executive Departure • Aug 11
Chairman of Scientific Advisory Board Tadataka Yamada has left the company On the 4th of August, Tadataka Yamada's tenure as Chairman of Scientific Advisory Board ended after 5.3 years in the role. We don't have any record of a personal shareholding under Tadataka's name. Tadataka is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.17 years. Executive Departure • Aug 05
Chairman of Scientific Advisory Board Tadataka Yamada has left the company On the 3rd of August, Tadataka Yamada's tenure as Chairman of Scientific Advisory Board ended after 5.3 years in the role. We don't have any record of a personal shareholding under Tadataka's name. Tadataka is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.17 years. Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥114, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 44x in the Biotechs industry in China. Total returns to shareholders of 62% over the past three years. Announcement • Jul 04
BGI Genomics Co., Ltd. (SZSE:300676) completed the acquisition of remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd. BGI Genomics Co., Ltd. (SZSE:300676) agreed to acquire the remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd. for CNY 2.37 million on April 22, 2021. B. BGI Genomics Co., Ltd shall pay the Beijing Research Center in one lump sum by bank transfer in accordance with the currency and amount specified in the above clauses within 90 days from the effective date of this agreement. The funds for this transaction come from BGI Genomics Co., Ltd. own funds. Beijing BGI Medical Laboratory Co., Ltd. reported total assets of CNY 47.5053 million and net assets of CNY -5.59 million for March 31, 2021. The board of directors of BGI Genomics Co., Ltd. approved the transaction in the 30th meeting of the second board of directors held on April 22, 2021.
BGI Genomics Co., Ltd. (SZSE:300676) completed the acquisition of remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd. on July 2, 2021. Announcement • Jun 26
Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China Natera, Inc. and BGI Genomics Co., Ltd. announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China. Natera's Signatera® assay, now offered in partnership with BGI,1 has been utilized in numerous clinical studies across non-small cell lung, bladder, breast and colorectal cancers, to identify molecular residual disease (MRD) up to two years earlier than standard imaging. The test is now available in China under the Chinese brand name Hua Jian Wei for short. Announcement • May 21
BGI Genomics Co., Ltd. Approves Cash Dividend for 2020 BGI Genomics Co., Ltd. at its AGM held on May 18, 2021, approved cash dividend of CNY 3.50000000 per 10 shares (tax included) for 2020. Announcement • Apr 27
BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2020 BGI Genomics Co., Ltd. announced on April 26, 2021 the profit distribution proposal for 2020 as cash dividend/10 shares (tax included) of CNY 3.50000000. Reported Earnings • Apr 26
First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.35 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.56b (up 98% from 1Q 2020). Net income: CN¥525.0m (up 275% from 1Q 2020). Profit margin: 34% (up from 18% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 08
New 90-day low: CN¥125 The company is down 5.0% from its price of CN¥132 on 08 December 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.01 per share. Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥5.23 (vs CN¥0.69 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥8.43b (up 201% from FY 2019). Net income: CN¥2.08b (up CN¥1.80b from FY 2019). Profit margin: 25% (up from 9.9% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Mar 04
Revenue and earnings miss expectations Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) also missed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 36% compared to a 57% growth forecast for the Biotechs industry in China. Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment deteriorated over the past week After last week's 22% share price decline to CN¥139, the stock is trading at a trailing P/E ratio of 20.4x, down from the previous P/E ratio of 26.2x. This compares to an average P/E of 62x in the Biotechs industry in China. Total return to shareholders over the past three years is a loss of 6.8%. Is New 90 Day High Low • Jan 21
New 90-day high: CN¥166 The company is up 25% from its price of CN¥133 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥0.93 per share. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥148, the stock is trading at a trailing P/E ratio of 21.7x, up from the previous P/E ratio of 18.8x. This compares to an average P/E of 66x in the Biotechs industry in China. Total return to shareholders over the past three years is a loss of 23%. Is New 90 Day High Low • Dec 18
New 90-day low: CN¥127 The company is down 10.0% from its price of CN¥142 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.51 per share. Is New 90 Day High Low • Nov 11
New 90-day low: CN¥133 The company is down 12% from its price of CN¥150 on 13 August 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.34 per share. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥2.71b, with earnings increasing by CN¥2.38b from the prior year. Total revenue was CN¥7.48b over the last 12 months, up 168% from the prior year. Is New 90 Day High Low • Oct 23
New 90-day low: CN¥133 The company is down 12% from its price of CN¥151 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.22 per share. Announcement • Aug 11
BGI Genomics Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020 BGI Genomics Co., Ltd. announced that they will report first half, 2020 results on Aug 27, 2020 Announcement • Jul 08
BGI Genomics Co., Ltd. announced that it expects to receive CNY 2.0119372 billion in funding BGI Genomics Co., Ltd. (SZSE:300676) announced a private placement of not exceeding 40,010,000 shares for gross proceeds not exceeding of not exceeding CNY 2,011,937,200. Issuance price will be not lower than 80% of the average price of the company’s shares as of 20 trading days since issuance date. The shares issues will have a hold period of 6 months from the date of closing. The transaction included participation from not more than 35 specific investors prescribed by the China Securities Regulatory Commission. The transaction has been approved by board of directors at the 22nd meeting of the second. The transaction is subject to approval by the shareholders, Shenzhen Stock Exchange, and China Securities Regulatory Commission. 
